Geode Capital Management LLC Purchases 25,776 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Geode Capital Management LLC raised its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 4.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 581,958 shares of the biopharmaceutical company’s stock after purchasing an additional 25,776 shares during the quarter. Geode Capital Management LLC’s holdings in Emergent BioSolutions were worth $4,861,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new position in Emergent BioSolutions during the 2nd quarter valued at $41,000. Stifel Financial Corp purchased a new stake in shares of Emergent BioSolutions during the third quarter valued at $96,000. FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the third quarter worth about $103,000. Vanguard Personalized Indexing Management LLC purchased a new position in Emergent BioSolutions in the 2nd quarter worth about $93,000. Finally, Morse Asset Management Inc bought a new stake in Emergent BioSolutions during the 2nd quarter valued at about $97,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $10.32 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $559.18 million, a price-to-earnings ratio of -2.52 and a beta of 1.60. The firm has a 50 day moving average of $9.27 and a 200 day moving average of $8.98. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Benchmark upped their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. HC Wainwright began coverage on Emergent BioSolutions in a report on Monday, December 30th. They issued a “buy” rating and a $15.00 target price for the company. Finally, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday, December 28th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.